Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination With the CDK4/6 Inhibitor Abemaciclib in Patients With NUT Carcinoma, Breast Cancer and Other Solid Tumors

NCT05372640 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT05372640
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05372640 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of BET Bromodomain Inhibitor ZEN003694 in Combination With the CDK4/6 Inhibitor Abemaciclib in Patients With NUT Carcinoma, Breast Cancer and Other Solid Tumors
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Recruiting
Start date
August 10, 2023
Completion date
June 7, 2027
Enrollment
45 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iii breast cancer ajcc v8, anatomic stage iv breast cancer ajcc v8, metastatic breast carcinoma, metastatic malignant solid neoplasm, metastatic nut carcinoma, unresectable breast carcinoma, unresectable malignant solid neoplasm, unresectable nut carcinoma